Development of Cell Selective particle irradiation using epithermal neutron beam for malignant brain tumor.

使用超热中子束进行细胞选择性粒子照射治疗恶性脑肿瘤的进展。

基本信息

批准号：
17390390
负责人：
MATSUMURA Akira
金额：
$ 10.12万
依托单位：
University of Tsukuba
依托单位国家：
日本
项目类别：
Grant-in-Aid for Scientific Research (B)
财政年份：
2005
资助国家：
日本
起止时间：
2005 至 2007
项目状态：
已结题

来源：
https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-17390390/
关键词：
Glioma BNCT Boron Neutron Brain Tumor 脳腫瘍 BMCT グリオブラストーマ

项目摘要

Clinical trial of BNCT for GlioblastomaEight patients with histological proven glioblastoma with an average age of 65 years (range 32-76, M:F=2:6) were underwent BNCF with new protocol which add 30Gy X ray irradiation after BNCT. 7 patients were treated with intra-operative BNCT before the protocol. In these 15 cases, 5 cases are alive; the average post BNCT follow up period was 20.3 months. Time to progression was 11.9 months, overall survival was 25.3 months. Adverse event (Grade 3>) were seen in 2 cases; convulsion and brain swelling (1 case) and transient oculomotor palsy (1 case). These result superior to standard treatments and suggest the effectiveness of the BNCT for malignant gliomaMR spectroscopyFor estimating absolute concentration of boron compounds in tissue, proton MR spectroscopy (MRS) was applied to quantify phenylalanine and L-p-boronophenylalanine (BPA). We could identify several characteristic resonances, peak of 7.32ppm (phenylalanine), four peak ranged 7.1 ppm to 7.6 ppm (BPA). A water phantom were used, and absolute concentration were obtained by proton MRS using a tissue water signal as an internal standards. These methods have high correlation between the calculated concentrations based on MRS and the known concentration. (R=0.99: phenylalanine and BPA).These clinical results appear to encouraging, but the effectiveness of the invading tumor cells are still unclear. Improved tumor targeting boron delivery and neutron distribution will enhance the therapeutic effectiveness of BNCT.MR spectroscopy results indicate that proton MRS can be non-invasive and potentially useful technique for BPA quantification in BNCT.

BNCT对组织学证明的胶质母细胞瘤患者的BNCT临床试验，平均年龄为65岁（范围32-76，m：f = 2：6），BNCF使用了新方案，这些方案添加了30GY X射线辐照。在该方案之前，将7例患者用术中BNCT治疗。在这15例中，有5例还活着； BNCT后的平均随访期为20.3个月。进展时间为11.9个月，总生存期为25.3个月。在2例中看到不良事件（3级>）；抽搐和脑肿胀（1例）和瞬态眼动作麻痹（1例）。这些结果优于标准处理，并表明BNCT对组织中硼龙化合物的绝对浓度估计组织中硼MR光谱（MRS）的有效性，以量化苯丙氨酸和L-P-P-Poronopholonylanine（BPA）。我们可以识别几种特征共振，峰为7.32ppm（苯丙氨酸），四个峰值为7.1 ppm至7.6 ppm（BPA）。使用了水幻影，并使用组织水信号作为内部标准来通过质子MRS获得绝对浓度。这些方法基于MRS和已知浓度在计算的浓度之间具有很高的相关性。（r = 0.99：苯丙氨酸和BPA）。这些临床结果似乎令人鼓舞，但入侵的肿瘤细胞的有效性仍不清楚。改善靶向硼递送和中子分布的肿瘤将增强BNCT的治疗有效性。MR光谱结果表明，质子MRS可能是无创的，并且可能是BPA定量BNCT的潜在有用技术。

项目成果

期刊论文数量（0）

专著数量（0）

科研奖励数量（0）

会议论文数量（0）

专利数量（0）

Boron neutron capture therapy for glioblastoma

DOI：
10.1016/j.canlet.2008.01.021
发表时间：
2008-04-18
期刊：
CANCER LETTERS
影响因子：
9.7
作者：
Yamamoto, Tetsuya;Nakai, Kei;Matsumura, Akira
通讯作者：
Matsumura, Akira

Dosimetry for Neutron capture Therapy in JRR-4

JRR-4 中子俘获疗法的剂量测定

DOI：
发表时间：
2007
期刊：
Japanese Journal of Health Physics 4281
影响因子：
0
作者：
Kumada H;Yamamoto T
通讯作者：
Yamamoto T

Histopathological evaluation of glioblastoma after high-dose radiation therapy

高剂量放射治疗后胶质母细胞瘤的组织病理学评估

DOI：
发表时间：
2007
期刊：
影响因子：
0
作者：
Tsurubuchi T;Yamamoto T;Enomoto T;Sato M;Sakamoto N;Matsuda M;Marushima A;Nakai K;Saito A;Shibata Y;Tsuboi K;Matsumura. A
通讯作者：
Matsumura. A

Effects of combined treatment using sodium borocaptate(BSH) and buthionine sulfoximide(BSO) in a rat tumor model

硼己酸钠（BSH）与丁硫氨酸亚磺酰亚胺（BSO）联合治疗大鼠肿瘤模型的效果